Editoren is indicated for the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of the designated microorganisms in the conditions listed below: Acute Bacterial Exacerbation of Chronic Bronchitis Community Acquired Pneumonia Pharyngitis Tonsillitis Uncomplicated Skin and Skin-Structure Infections
Cefditoren is a preparation of Cefditoren Pivoxil which is a broad spectrum third generation cephalosporin antibiotic. Cefditoren is a prodrug which is hydrolyzed by esterases during absorption, and the drug is distributed in the circulating blood as active Cefditoren. Cefditoren has antibacterial activity against gram-positive and gram-negative pathogens. The bactericidal activity of Cefditoren results from the inhibition of cell wall synthesis via affinity for penicillin- binding proteins (PBPs). Cefditoren is stable in the presence of a variety of ß-lactamases, including penicillinases and some cephalosporinases.
Cefditoren should be taken after meals. Community-Acquired Pneumonia : 400 mg twice daily for 14 days. Acute Exacerbation of Chronic Bronchitis : 400 mg twice daily for 10 days. Pharyngotonsillitis and Acute Sinusitis : 200 mg twice daily for 10 days. Uncomplicated Skin and Soft Structure Infections : 200 mg twice daily for 10 days.
The most common side effects of Editoren are diarrhea, nausea, headache, abdominal pain, vaginal moniliasis, dyspepsia, vomiting, abnormal dreams, allergic reaction, anorexia, constipation, dizziness, dry mouth and fever.
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
Cefditoren is contraindicated in patients with known allergy to the cephalosporin class of antibiotics or any of its components. Cefditoren contain sodium caseinate, a milk protein. Patients with milk protein hypersensitivity (not lactose intolerance) should not be administered Cefditoren.
Antacids and Famotidine (intravenous administration) reduced the oral absorption of Editoren. As with other ß-lactam antibiotics, co-administration of probenecid with Editoren Pivoxil resulted in an increase in the plasma exposure of Editoren. Multiple doses of Editoren had no effect on the pharmacokinetics of ethinyl estradiol, the estrogenic component in most oral contraceptives.
Editoren is not recommended when prolonged antibiotic treatment is necessary, since other pivalate-containing compounds have caused clinical manifestations of carnitine deficiency when used over a period of months. Prescribing Editoren in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.